Explain this page
Arphra AIPlain-English read on Omeros Corporation’s valuation06-15today
- Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?2d
- Omeros Announces Webcast Details for Annual Meeting of Shareholders7d
- Omeros Announces Webcast Details for Annual Meeting of Shareholders7d
- Bears are Losing Control Over Omeros (OMER), Here's Why It's a 'Buy' Now18d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
1 of 2 methods
Method spread
0bull1bear
±5% threshold
Analyst PT consensus: $40.00 (+289.11%)
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00% | +8.90% | -10.30% | -6.55% | +8.10% | -40.16% | +222.26% | +80.04% | -33.51% | -5.34% | +17.75% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$10.28
14 sh
Bid
$10.27
10 sh
Ask
$10.29
10 sh
Spread
$0.020
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 Dec 2025 | $0 | $86.45M | $1.42 |
| Q3 Sep 2025 | $0 | -$30.92M | $-0.47 |
| Q2 Jun 2025 | $0 | -$25.42M | $-0.43 |
| Q1 Mar 2025 | $0 | -$33.46M | $-0.58 |
| Q4 Dec 2024 | $0 | -$31.36M | $-0.54 |
| Q3 Sep 2024 | $0 | -$32.23M | $-0.56 |
Sector & industry today
LiveSectors
- Real Estate+1.03%
- Basic Materials+0.80%
- Industrials+0.46%
- Consumer Cyclical+0.13%
- Consumer Defensive-0.01%
- Financial Services-0.05%
- Healthcare-0.32%
- Energy-0.34%
- Utilities-0.75%
- Communication Services-0.76%
- Technology-0.90%
Top industries (issuer's industry highlighted)
- Biotechnology+4.48%
- Oil & Gas Energy-5.20%
- Electronic Gaming & Multimedia-3.15%
- Residential Construction+3.15%
- Staffing & Employment Services-2.65%
- Financial - Mortgages-2.33%
- Construction Materials+2.32%
- Software - Infrastructure-2.29%
- Apparel - Footwear & Accessories-2.29%
- REIT - Specialty+2.23%
- Beverages - Wineries & Distilleries+2.23%
- Advertising Agencies+2.09%
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?fool.com·Jun 20, 2026
- Omeros Announces Webcast Details for Annual Meeting of Shareholdersbusinesswire.com·Jun 15, 2026
- Omeros Announces Webcast Details for Annual Meeting of Shareholdersbusinesswire.com·Jun 15, 2026
- Bears are Losing Control Over Omeros (OMER), Here's Why It's a 'Buy' Nowzacks.com·Jun 04, 2026
- Omeros Corporation Reports First Quarter 2026 Financial Resultsbusinesswire.com·May 13, 2026
- Omeros Corporation Reports First Quarter 2026 Financial Resultsbusinesswire.com·May 13, 2026
- Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026businesswire.com·May 11, 2026
Recent analyst activity
DB- Jun 10, 2026GradeBuy → BuyH.C. Wainwright Reiterates Buy Rating on Omeros Corp. (OMER)H.C. Wainwright
Peers
No peer list available for OMER.
Total assets
$325.63M
Total debt
$239.14M
Cash & equiv
$9.66M
Operating CF
-$116.09M
Free cash flow
-$116.16M
Buybacks
$0
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $0 | -$122.8M | -$3.35M | $-0.05 | — |
| FY 2024 | $0 | -$169.26M | -$156.82M | $-2.70 | — |
| FY 2023 | $0 | -$164.53M | -$117.81M | $-1.88 | — |
| FY 2022 | $0 | -$163.39M | $47.42M | $0.46 | — |
| FY 2021 | $0 | -$173.62M | -$111.41M | $3.12 | — |